Objective: This study was conducted to investigate neuroprotective effects of a high fat/low carbohydrate and protein diet (ketogenic diet, KD) in a model of N-methyl D-aspartate (NMDA)-induced retinal ganglion cell (RGC) damage in juvenile and young adult rats. Methods: Juvenile (30-35 days old) and young adult (56-70 days old) female Brown Norway rats were fed the KD for 21 days; rats exposed to a standard rodent diet (SRD) served as controls. The main constituents of the KD used in the present study were approximately 80% fats, 8% proteins, and less than 1% carbohydrates. On day 14 of exposure to the KD (or the SRD in the control group), each rat received a single intravitreal injection of NMDA; RGCs were then retrogradely labelled by hydroxystilbamidine on day 19 and collected on day 21 to assess the degree of damage induced by NMDA. Blood biomarkers to confirm the expected metabolic response to the KD (i.e. ketosis and hypoglycaemia) were also assessed. Results: Although both the juvenile and young adult rats developed comparable ketosis and hypoglycaemia when fed the KD, NMDA-induced loss in RGCs was significantly attenuated only in juvenile rats exposed to the KD in comparison with those fed the SRD; exposure to the KD had no protective effect in young adult rats. In summary, exposure to the KD had a neuroprotective effect in NMDA-induced RGC damage in juvenile rats, but not in young adult rats. Conclusion: These results support further exploration of metabolic interventions to treat optic neuropathies associated with neurodegeneration.

1.
Zhang K, Zhang L, Weinreb RN: Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov 2012;11:541-559.
2.
Gasior M, Rogawski MA, Hartman AL: Neuroprotective and disease-modifying effects of the ketogenic diet. Behav Pharmacol 2006;17:431-439.
3.
Hartman AL: Neuroprotection in metabolism-based therapy. Epilepsy Res 2012;100:286-294.
4.
Zarnowski T, Tulidowicz-Bielak M, Kosior-Jarecka E, Zarnowska I, Turski WA, Gasior M: A ketogenic diet may offer neuroprotection in glaucoma and mitochondrial diseases of the optic nerve. Med Hypothesis Discov Innov Ophthalmol 2012;1:45-49.
5.
Kawai SI, Vora S, Das S, Gachie E, Becker B, Neufeld AH: Modeling of risk factors for the degeneration of retinal ganglion cells after ischemia/reperfusion in rats: effects of age, caloric restriction, diabetes, pigmentation, and glaucoma. FASEB J 2001;15:1285-1287.
6.
Kong YX, van BN, Bui BV, Chrysostomou V, Vingrys AJ, Trounce IA, Crowston JG: Impact of aging and diet restriction on retinal function during and after acute intraocular pressure injury. Neurobiol Aging 2012;33:1126.
7.
Casson RJ: Possible role of excitotoxicity in the pathogenesis of glaucoma. Clin Experiment Ophthalmol 2006;34:54-63.
8.
Bough KJ, Valiyil R, Han FT, Eagles DA: Seizure resistance is dependent upon age and calorie restriction in rats fed a ketogenic diet. Epilepsy Res 1999;35:21-28.
9.
Rho JM, Kim DW, Robbins CA, Anderson GD, Schwartzkroin PA: Age-dependent differences in flurothyl seizure sensitivity in mice treated with a ketogenic diet. Epilepsy Res 1999;37:233-240.
10.
Prins ML, Fujima LS, Hovda DA: Age-dependent reduction of cortical contusion volume by ketones after traumatic brain injury. J Neurosci Res 2005;82:413-420.
11.
Hartman AL, Lyle M, Rogawski MA, Gasior M: Efficacy of the ketogenic diet in the 6-Hz seizure test. Epilepsia 2008;49:334-339.
12.
Zarnowski T, Choragiewicz T, Tulidowicz-Bielak M, Thaler S, Rejdak R, Zarnowska I, Turski WA, Gasior M: Ketogenic diet increases concentrations of kynurenic acid in discrete brain structures of young and adult rats. J Neural Transm 2012;119:679-684.
13.
Thaler S, Choragiewicz TJ, Rejdak R, Fiedorowicz M, Turski WA, Tulidowicz-Bielak M, Zrenner E, Schuettauf F, Zarnowski T: Neuroprotection by acetoacetate and beta-hydroxybutyrate against NMDA-induced RGC damage in rat - possible involvement of kynurenic acid. Graefes Arch Clin Exp Ophthalmol 2010;248:1729-1735.
14.
Salinas-Navarro M, Mayor-Torroglosa S, Jimenez-Lopez M, Aviles-Trigueros M, Holmes TM, Lund RD, Villegas-Perez MP, Vidal-Sanz M: A computerized analysis of the entire retinal ganglion cell population and its spatial distribution in adult rats. Vision Res 2009;49:115-126.
15.
Dahlquist G, Persson B: The rate of cerebral utilization of glucose, ketone bodies, and oxygen: a comparative in vivo study of infant and adult rats. Pediatr Res 1976;10:910-917.
16.
Yeh YY, Sheehan PM: Preferential utilization of ketone bodies in the brain and lung of newborn rats. Fed Proc 1985;44:2352-2358.
17.
Nehlig A: Age-dependent pathways of brain energy metabolism: the suckling rat, a natural model of the ketogenic diet. Epilepsy Res 1999;37:211-221.
18.
Gerhart DZ, Leino RL, Drewes LR: Distribution of monocarboxylate transporters MCT1 and MCT2 in rat retina. Neuroscience 1999;92:367-375.
19.
Leino RL, Gerhart DZ, Duelli R, Enerson BE, Drewes LR: Diet-induced ketosis increases monocarboxylate transporter (MCT1) levels in rat brain. Neurochem Int 2001;38:519-527.
20.
Sanguino E, Ramon M, Michalik L, Wahli W, Alegret M, Sanchez RM, Vazquez-Carrera M, Laguna JC: Lack of hypotriglyceridemic effect of gemfibrozil as a consequence of age-related changes in rat liver PPARalpha. Biochem Pharmacol 2004;67:157-166.
21.
Marks JD, Bindokas VP, Zhang XM: Maturation of vulnerability to excitotoxicity: intracellular mechanisms in cultured postnatal hippocampal neurons. Brain Res Dev Brain Res 2000;124:101-116.
22.
Cady C, Evans MS, Brewer GJ: Age-related differences in NMDA responses in cultured rat hippocampal neurons. Brain Res 2001;921:1-11.
23.
Kannurpatti SS, Sanganahalli BG, Mishra S, Joshi PG, Joshi NB: Glutamate-induced differential mitochondrial response in young and adult rats. Neurochem Int 2004;44:361-369.
24.
Ueda K, Nakahara T, Hoshino M, Mori A, Sakamoto K, Ishii K: Retinal blood vessels are damaged in a rat model of NMDA-induced retinal degeneration. Neurosci Lett 2010;485:55-59.
25.
Maalouf M, Rho JM, Mattson MP: The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res Rev 2009;59:293-315.
26.
Kido N, Tanihara H, Honjo M, Inatani M, Tatsuno T, Nakayama C, Honda Y: Neuroprotective effects of brain-derived neurotrophic factor in eyes with NMDA-induced neuronal death. Brain Res 2000;884:59-67.
27.
Rejdak R, Zarnowski T, Turski WA, Kocki T, Zagorski Z, Zrenner E, Schuettauf F: Alterations of kynurenic acid content in the retina in response to retinal ganglion cell damage. Vision Res 2003;43:497-503.
28.
Schuettauf F, Zurakowski D, Quinto K, Varde MA, Besch D, Laties A, Anderson R, Wen R: Neuroprotective effects of cardiotrophin-like cytokine on retinal ganglion cells. Graefes Arch Clin Exp Ophthalmol 2005;243:1036-1042.
29.
Inomata Y, Nakamura H, Tanito M, Teratani A, Kawaji T, Kondo N, Yodoi J, Tanihara H: Thioredoxin inhibits NMDA-induced neurotoxicity in the rat retina. J Neurochem 2006;98:372-385.
30.
Hartman AL, Gasior M, Vining EP, Rogawski MA: The neuropharmacology of the ketogenic diet. Pediatr Neurol 2007;36:281-292.
31.
Bough KJ, Eagles DA: A ketogenic diet increases the resistance to pentylenetetrazole-induced seizures in the rat. Epilepsia 1999;40:138-143.
32.
Jarrett SG, Milder JB, Liang LP, Patel M: The ketogenic diet increases mitochondrial glutathione levels. J Neurochem 2008;106:1044-1051.
33.
Lan YW, Ishii Y, Palmer KE, Bristow KQ, Caprioli J, Kwong JM: 2-Deoxy-D-glucose protects retinal ganglion cells against excitotoxicity. Neuroreport 2003;14:2369-2372.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.